Iron and B12 Supplements Should Be AVOIDED in Polycythemia Vera
Iron and vitamin B12 supplements should generally be discontinued in patients with polycythemia vera, as both can exacerbate erythrocytosis and increase thrombotic risk, which directly contradicts the primary treatment goal of reducing red blood cell mass.
Iron Supplementation: Contraindicated
Iron deficiency is nearly universal in PV patients, occurring both at diagnosis and during treatment, particularly with phlebotomy 1, 2. However, this iron deficiency is therapeutically beneficial rather than harmful:
Why Iron Should NOT Be Replaced:
- Iron deficiency limits erythropoiesis - This naturally helps control hematocrit levels without additional interventions 1
- Phlebotomy intentionally creates iron deficiency - This is the mechanism by which phlebotomy works to reduce red cell mass 2
- Iron repletion worsens disease control - Giving iron will increase hemoglobin and hematocrit, raising thrombotic risk 3
The One Narrow Exception:
In rare cases of severe, intractable pruritus with documented iron deficiency, a short 2-3 week course of iron supplementation may provide symptomatic relief 3. However, this must be:
- Limited to 2-3 weeks after symptom resolution
- Closely monitored for rising hemoglobin/hematocrit
- Stopped immediately if red cell mass increases unacceptably 3
- Recognized that pruritus will likely recur when iron is discontinued 3
This exception prioritizes quality of life in extreme circumstances but requires intensive monitoring given the increased thrombotic risk.
Vitamin B12 Supplementation: Also Contraindicated
B12 supplementation can unmask or worsen polycythemia vera 4, 5:
Key Concerns:
- FDA labeling explicitly lists polycythemia vera as an adverse reaction to B12 administration 4
- B12 deficiency can actually mask PV by causing megaloblastic anemia that suppresses the elevated red cell counts 5
- Correcting B12 deficiency in PV patients will increase erythrocyte production, worsening the polycythemia 5
- B12 can produce hematologic response even in doses exceeding 10 mcg daily 4
Clinical Pitfall:
The coexistence of B12 deficiency and PV creates a diagnostic challenge. B12 deficiency may mask iron deficiency 6, and correcting B12 can reveal both the underlying PV and concurrent iron deficiency. If B12 deficiency is corrected, expect hematocrit to rise and phlebotomy requirements to increase.
When B12 Might Be Necessary:
Only consider B12 if there is documented neurologic compromise from B12 deficiency (subacute combined degeneration), as this represents irreversible morbidity if untreated beyond 3 months 4. In this scenario:
- Use the minimum effective dose
- Intensify hematocrit monitoring
- Increase phlebotomy frequency as needed
- Consider adding or escalating cytoreductive therapy
The Treatment Paradigm in PV
The goal is hematocrit control below 45% to minimize thrombotic events 7, 8. This is achieved through:
- Phlebotomy - First-line for all patients, which deliberately induces iron deficiency 7, 1
- Cytoreductive therapy - For high-risk patients (age ≥60 or prior thrombosis) using hydroxyurea, interferon-α, or ruxolitinib 7, 9
- Low-dose aspirin - For thrombosis prevention 7
Supplementing iron or B12 works against these treatment goals by stimulating erythropoiesis, increasing red cell mass, and elevating thrombotic risk—the primary cause of morbidity and mortality in PV.
Quality of Life Considerations
While iron deficiency causes fatigue, lethargy, and impaired concentration 1, and phlebotomy is burdensome 8, the mortality risk from thrombosis outweighs these quality-of-life concerns. The appropriate response to symptomatic iron deficiency is:
- Optimization of cytoreductive therapy to reduce phlebotomy frequency 8
- Consideration of newer agents like hepcidin mimetics (rusfertide) that control hematocrit without requiring phlebotomy 1
- NOT iron supplementation, which increases thrombotic risk
In summary: Stop both iron and B12 supplements in PV patients unless there is documented, irreversible neurologic B12 deficiency requiring the minimum necessary replacement with intensified disease monitoring.